The correlation results suggest a hypothesis where HCRT, a neurotransmitter only produced in the hypothalamus and related to the wake/sleep cycle, could be a relatively more important candidate as a blocker or promoter when compared to EPO, a glycoprotein hormone produced by kidney and liver, for targeting drug development with application to Alzheimer's disease clinical trials. The gene discussed is HCRT; the disease is Alzheimer disease.